Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

30 / 39

Mutational profile guides treatment
Shaw – NEJM 2016 * Okada – EbioMED 2019
Resensitization to crizotinib
by the lorlatinib ALK
Resistance mutation L1198F